ID Database Citation 10.2174/9781681081946116010017 DOI "Biomolecular Pathways and Malignant Pleural Mesothelioma. Jaurand MC, Jean D. In: Malignant Pleural Mesothelioma: Present Status and Future Directions [Internet]. BENTHAM SCIENCE PUBLISHERS; 2016. p. 169–92. Available from: http://dx.doi.org/10.2174/9781681081946116010017 DOI Scholia" 9378538 Pubmed "Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Klominek J, Sumitran Karuppan S, Hauzenberger D. Int J Cancer. 1997 Sep 17;72(6):1034–44. PubMed Europe PMC Scholia" 12589646 Pubmed "The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Illei PB, Ladanyi M, Rusch VW, Zakowski MF. Cancer. 2003 Feb 25;99(1):51–6. PubMed Europe PMC Scholia" 12612292 Pubmed "Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Liu Z, Klominek J. Thorax. 2003 Mar;58(3):198–203. PubMed Europe PMC Scholia" 12771921 Pubmed "Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Edwards JG, McLaren J, Jones JL, Waller DA, O’Byrne KJ. Br J Cancer. 2003 May 19;88(10):1553–9. PubMed Europe PMC Scholia" 15686623 Pubmed "Wnt signaling in disease and in development. Nusse R. Cell Res. 2005 Jan;15(1):28–32. PubMed Europe PMC Scholia" 16216411 Pubmed "Molecular pathways in malignant pleural mesothelioma. Whitson BA, Kratzke RA. Cancer Lett. 2006 Aug 8;239(2):183–9. PubMed Europe PMC Scholia" 19753302 Pubmed "Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, et al. PLoS One. 2009 Sep 15;4(9):e7016. PubMed Europe PMC Scholia" 21484256 Pubmed "An emerging model for BAP1’s role in regulating cell cycle progression. Eletr ZM, Wilkinson KD. Cell Biochem Biophys. 2011 Jun;60(1–2):3–11. PubMed Europe PMC Scholia" 23395095 Pubmed "New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R. Am J Pathol. 2013 Apr;182(4):1065–77. PubMed Europe PMC Scholia" 23550303 Pubmed "BAP1 and cancer. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. Nat Rev Cancer. 2013 Mar;13(3):153–9. PubMed Europe PMC Scholia" 23975423 Pubmed "Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Sallé F, Cazes A, et al. Oncogene. 2014 Jul 10;33(28):3748–52. PubMed Europe PMC Scholia" 24607545 Pubmed "RASSF tumor suppressor gene family: biological functions and regulation. Volodko N, Gordon M, Salla M, Ghazaleh HA, Baksh S. FEBS Lett. 2014 Aug 19;588(16):2671–84. PubMed Europe PMC Scholia" 24780002 Pubmed "The ins and outs of fibroblast growth factor receptor signalling. Coleman SJ, Bruce C, Chioni AM, Kocher HM, Grose RP. Clin Sci (Lond). 2014 Aug;127(4):217–31. PubMed Europe PMC Scholia" 26078352 Pubmed "Reactive oxygen species a double-edged sword for mesothelioma. Benedetti S, Nuvoli B, Catalani S, Galati R. Oncotarget. 2015 Jul 10;6(19):16848–65. PubMed Europe PMC Scholia" 26358421 Pubmed "Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Urso L, Calabrese F, Favaretto A, Conte P, Pasello G. Crit Rev Oncol Hematol. 2016 Jan;97:220–30. PubMed Europe PMC Scholia" 27282309 Pubmed "The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. Hylebos M, Van Camp G, van Meerbeeck JP, Op de Beeck K. J Thorac Oncol. 2016 Oct;11(10):1615–26. PubMed Europe PMC Scholia" 27300434 Pubmed "YAP/TAZ at the Roots of Cancer. Zanconato F, Cordenonsi M, Piccolo S. Cancer Cell. 2016 Jun 13;29(6):783–803. PubMed Europe PMC Scholia" 27507853 Pubmed "Genomic Landscape of Malignant Mesotheliomas. Kato S, Tomson BN, Buys TPH, Elkin SK, Carter JL, Kurzrock R. Mol Cancer Ther. 2016 Oct;15(10):2498–507. PubMed Europe PMC Scholia" 28327630 Pubmed "Rassf Proteins as Modulators of Mst1 Kinase Activity. Bitra A, Sistla S, Mariam J, Malvi H, Anand R. Sci Rep. 2017 Mar 22;7:45020. PubMed Europe PMC Scholia" 28614305 Pubmed "BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, et al. Nature. 2017 Jun 22;546(7659):549–53. PubMed Europe PMC Scholia" 28740119 Pubmed "Novel insights into mesothelioma biology and implications for therapy. Yap TA, Aerts JG, Popat S, Fennell DA. Nat Rev Cancer. 2017 Jul 25;17(8):475–88. PubMed Europe PMC Scholia" 29371938 Pubmed "Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Hylebos M, Van Camp G, Vandeweyer G, Fransen E, Beyens M, Cornelissen R, et al. Oncotarget. 2017 Dec 1;8(69):113673–86. PubMed Europe PMC Scholia" 29565815 Pubmed "Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Sekido Y. Cancers (Basel). 2018 Mar 22;10(4):90. PubMed Europe PMC Scholia" 30073421 Pubmed "The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. Liu XL, Zuo R, Ou WB. J Cancer Res Clin Oncol. 2018 Nov;144(11):2097–106. PubMed Europe PMC Scholia" 30101371 Pubmed "Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Dobrokhotov O, Samsonov M, Sokabe M, Hirata H. Clin Transl Med. 2018 Aug 13;7(1):23. PubMed Europe PMC Scholia" 30642555 Pubmed "Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Chapel DB, Churg A, Santoni-Rugiu E, Tsujimura T, Hiroshima K, Husain AN. Lung Cancer. 2019 Jan;127:69–75. PubMed Europe PMC Scholia" 31283845 Pubmed "Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. CA Cancer J Clin. 2019 Sep;69(5):402–29. PubMed Europe PMC Scholia" 31285550 Pubmed "Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Yuan X, Larsson C, Xu D. Oncogene. 2019 Aug;38(34):6172–83. PubMed Europe PMC Scholia" 31867277 Pubmed "The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Chu GJ, van Zandwijk N, Rasko JEJ. Front Oncol. 2019 Dec 6;9:1366. PubMed Europe PMC Scholia" 32317288 Pubmed "Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Pirker C, Bilecz A, Grusch M, Mohr T, Heidenreich B, Laszlo V, et al. Clin Cancer Res. 2020 Jul 15;26(14):3819–30. PubMed Europe PMC Scholia" 32768523 Pubmed "TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends. Yuan X, Dai M, Xu D. Cancer Lett. 2020 Nov 28;493:1–9. PubMed Europe PMC Scholia" 32882916 Pubmed "Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Cakiroglu E, Senturk S. Int J Mol Sci. 2020 Sep 1;21(17):6342. PubMed Europe PMC Scholia" 33232793 Pubmed "Fundamental insights into the interaction between telomerase/TERT and intracellular signaling pathways. Ghareghomi S, Ahmadian S, Zarghami N, Kahroba H. Biochimie. 2021 Feb;181:12–24. PubMed Europe PMC Scholia" 33329574 Pubmed "TERT-Regulation and Roles in Cancer Formation. Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. Front Immunol. 2020 Nov 19;11:589929. PubMed Europe PMC Scholia" 33462414 Pubmed "Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Masclef L, Ahmed O, Estavoyer B, Larrivée B, Labrecque N, Nijnik A, et al. Cell Death Differ. 2021 Feb;28(2):606–25. PubMed Europe PMC Scholia" 33800494 Pubmed "Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. Morani F, Bisceglia L, Rosini G, Mutti L, Melaiu O, Landi S, et al. Int J Mol Sci. 2021 Mar 8;22(5):2738. PubMed Europe PMC Scholia" 34073720 Pubmed "Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Napoli F, Listì A, Zambelli V, Witel G, Bironzo P, Papotti M, et al. Cancers (Basel). 2021 May 24;13(11):2564. PubMed Europe PMC Scholia" 34226685 Pubmed "Biological basis for novel mesothelioma therapies. Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, et al. Br J Cancer. 2021 Oct;125(8):1039–55. PubMed Europe PMC Scholia"